← Evidence map

ArticleThoracic cancer2026

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management.

Issei Oi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management. | OpenQuestion